Abstract
There is a clear need for both disease-modifying agents and alternative analgesic therapies in osteoarthritis. Currently, there are none of the former, and the latter are limited by adverse effects, particularly gastrointestinal and cardiovascular effects. A new class of analgesic agent that is under investigation inhibits 5-lipoxygenase (5-LOX), the enzyme that catalyzes the conversion of membrane-bound arachidonic acid to leukotrienes. As leukotrienes are implicated in a wide variety of pathologies, the potential of 5-LOX inhibitors has been explored in conditions as diverse as asthma, acute mountain sickness and coronary artery disease. A new 5-LOX inhibitor, derived from a herb, has undergone a phase II trial in osteoarthritis with promising results. Although a putative mechanism of action suggests a disease-modifying effect, the important outcomes from this trial are good symptom response and a low adverse effect profile, albeit in the small number of patients studied.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel in vitro inhibitory functions of potato tuber proteinaceous inhibitors
Molecular Genetics and Genomics Open Access 27 September 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Luo W et al. (2007) The burden of adult obesity in Canada. Chronic Dis Can 27: 135–144
Lopez AD et al. (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747–1757
Sengupta K et al. (2008) A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther 10: R85
Watkins PB et al. (2007) Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf 30: 805–815
Raynauld JP et al. (2008) Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multi-centre clinical trial using quantitative MRI. Ann Rheum Dis [doi:10.1136/ard.2008.088732]
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Williams, F., Spector, T. A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis. Nat Rev Rheumatol 5, 132–133 (2009). https://doi.org/10.1038/ncprheum1006
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum1006
This article is cited by
-
Novel in vitro inhibitory functions of potato tuber proteinaceous inhibitors
Molecular Genetics and Genomics (2015)